Price
Target price
€30.60
€30.60
2.700%
0.8
2.700%
€36.75
02.04.26 / Tradegate
WKN: A1W2RM / Symbol: AGIO / Name: Agios / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Agios Pharmaceuticals Inc. Stock
Agios Pharmaceuticals Inc. gained 2.700% today.
Agios Pharmaceuticals Inc. is currently one of the favorites of our community with 16 Buy predictions and no Sell predictions.
With a target price of 36 € there is a slightly positive potential of 17.65% for Agios Pharmaceuticals Inc. compared to the current price of 30.6 €.
So far the community has only identified positive things for Agios Pharmaceuticals Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Agios Pharmaceuticals Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
S********** s********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Agios Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc. | 2.700% | 19.531% | 22.400% | 15.909% | 31.897% | 42.991% | -31.467% |
| United Therapeutics | -1.950% | 4.439% | 11.379% | 69.931% | 14.533% | 143.725% | 198.415% |
| Ionis Pharmaceuticals Inc. | 0.830% | 0.621% | -7.530% | 144.957% | -4.591% | 96.634% | 69.428% |
| Novocure Ltd | -2.330% | -10.373% | -20.883% | -44.694% | -19.347% | -83.519% | -91.924% |
Comments
Agios Pharmaceuticals (AGIO) had its price target raised by Citigroup Inc. from $38.00 to $46.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) had its price target raised by analysts at HC Wainwright from $62.00 to $65.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) was given a new $40.00 price target on by analysts at Leerink Partners. They now have an "outperform" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
News
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today
Drugmaker Agios Pharmaceuticals (NASDAQ: AGIO) is positioning to win the FDA's approval of its mitapivat as a treatment for sickle cell disease sooner than investors may have been expecting.
That's
Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything
Viswanadhan Krishnan, Chief Corporate Development and Strategy Officer at Agios Pharmaceuticals (NASDAQ:AGIO), reported the open-market sale of 2,959 shares of common stock for a total of roughly
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer
On February 17, 2026, Commodore Capital disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold all 2,338,287 shares of Agios Pharmaceuticals (NASDAQ:AGIO) in the fourth